142 related articles for article (PubMed ID: 33868471)
21. The Role of Contactin 1 in Cancers: What We Know So Far.
Liang Y; Ma C; Li F; Nie G; Zhang H
Front Oncol; 2020; 10():574208. PubMed ID: 33194679
[TBL] [Abstract][Full Text] [Related]
22. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
[TBL] [Abstract][Full Text] [Related]
23. TASK-1 induces gefitinib resistance by promoting cancer initiating cell formation and epithelial-mesenchymal transition in lung cancer.
Wang XG; Yuan NX; Li XP; Chen FF
Exp Ther Med; 2018 Jan; 15(1):365-370. PubMed ID: 29387193
[TBL] [Abstract][Full Text] [Related]
24. Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation.
Pan Y; Li X; Duan J; Yuan L; Fan S; Fan J; Xiaokaiti Y; Yang H; Wang Y; Li X
Mol Pharmacol; 2015; 87(3):378-90. PubMed ID: 25488183
[TBL] [Abstract][Full Text] [Related]
25. Integrin β1-mediated acquired gefitinib resistance in non-small cell lung cancer cells occurs via the phosphoinositide 3-kinase-dependent pathway.
Deng QF; Su BO; Zhao YM; Tang L; Zhang J; Zhou CC
Oncol Lett; 2016 Jan; 11(1):535-542. PubMed ID: 26870244
[TBL] [Abstract][Full Text] [Related]
26. The Anoikis Effector Bit1 Inhibits EMT through Attenuation of TLE1-Mediated Repression of E-Cadherin in Lung Cancer Cells.
Yao X; Pham T; Temple B; Gray S; Cannon C; Chen R; Abdel-Mageed AB; Biliran H
PLoS One; 2016; 11(9):e0163228. PubMed ID: 27655370
[TBL] [Abstract][Full Text] [Related]
27. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
Zhou J; Hu Q; Zhang X; Zheng J; Xie B; Xu Z; Zhang W
Oncol Rep; 2018 Apr; 39(4):1783-1792. PubMed ID: 29393480
[TBL] [Abstract][Full Text] [Related]
28. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
29. WSTF promotes proliferation and invasion of lung cancer cells by inducing EMT via PI3K/Akt and IL-6/STAT3 signaling pathways.
Meng J; Zhang XT; Liu XL; Fan L; Li C; Sun Y; Liang XH; Wang JB; Mei QB; Zhang F; Zhang T
Cell Signal; 2016 Nov; 28(11):1673-82. PubMed ID: 27449264
[TBL] [Abstract][Full Text] [Related]
30. Gefitinib promotes CXCR4-dependent epithelial to mesenchymal transition via TGF-β1 signaling pathway in lung cancer cells harboring EGFR mutation.
Zhu Q; Zhang Z; Lu C; Xu F; Mao W; Zhang K; Shou H; Liu Z; Gu J; Ge D
Clin Transl Oncol; 2020 Aug; 22(8):1355-1363. PubMed ID: 31900845
[TBL] [Abstract][Full Text] [Related]
31. Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells.
Liu Z; Gao W
Toxicol Appl Pharmacol; 2017 Nov; 335():16-27. PubMed ID: 28942004
[TBL] [Abstract][Full Text] [Related]
32. Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer.
Yan J; Ojo D; Kapoor A; Lin X; Pinthus JH; Aziz T; Bismar TA; Wei F; Wong N; De Melo J; Cutz JC; Major P; Wood G; Peng H; Tang D
Cancer Res; 2016 Mar; 76(6):1603-14. PubMed ID: 26795349
[TBL] [Abstract][Full Text] [Related]
33. TLE1 promotes EMT in A549 lung cancer cells through suppression of E-cadherin.
Yao X; Ireland SK; Pham T; Temple B; Chen R; Raj MH; Biliran H
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):277-84. PubMed ID: 25446087
[TBL] [Abstract][Full Text] [Related]
34. Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K/Akt/NF-κB pathway.
Yu M; Qi B; Xiaoxiang W; Xu J; Liu X
Biomed Pharmacother; 2017 Jun; 90():677-685. PubMed ID: 28415048
[TBL] [Abstract][Full Text] [Related]
35. Gefitinib induces lung cancer cell autophagy and apoptosis via blockade of the PI3K/AKT/mTOR pathway.
Zhao ZQ; Yu ZY; Li J; Ouyang XN
Oncol Lett; 2016 Jul; 12(1):63-68. PubMed ID: 27347100
[TBL] [Abstract][Full Text] [Related]
36. SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals.
She K; Fang S; Du W; Fan X; He J; Pan H; Huang L; He P; Huang J
Cancer Cell Int; 2019; 19():103. PubMed ID: 31019378
[TBL] [Abstract][Full Text] [Related]
37. Lapatinib-induced mesenchymal-epithelial transition in squamous cell carcinoma cells correlates with unexpected alteration of β-catenin expression.
Umbreit C; Erben P; Faber A; Hofheinz RD; Schultz JD; Hoermann K; Wenzel A
Oncol Lett; 2016 Apr; 11(4):2715-2724. PubMed ID: 27073542
[TBL] [Abstract][Full Text] [Related]
38. Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway.
Ma W; Kang Y; Ning L; Tan J; Wang H; Ying Y
Exp Ther Med; 2017 Oct; 14(4):2853-2862. PubMed ID: 28912847
[TBL] [Abstract][Full Text] [Related]
39. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
40. Gefitinib suppresses cervical cancer progression by inhibiting cell cycle progression and epithelial-mesenchymal transition.
Zheng J; Yu J; Yang M; Tang L
Exp Ther Med; 2019 Sep; 18(3):1823-1830. PubMed ID: 31410143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
